557 related articles for article (PubMed ID: 24718990)
1. Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish.
Bonetti M; Paardekooper Overman J; Tessadori F; Noël E; Bakkers J; den Hertog J
Development; 2014 May; 141(9):1961-70. PubMed ID: 24718990
[TBL] [Abstract][Full Text] [Related]
2. Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects.
Jopling C; van Geemen D; den Hertog J
PLoS Genet; 2007 Dec; 3(12):e225. PubMed ID: 18159945
[TBL] [Abstract][Full Text] [Related]
3. Phosphoproteomics-mediated identification of Fer kinase as a target of mutant Shp2 in Noonan and LEOPARD syndrome.
Paardekooper Overman J; Preisinger C; Prummel K; Bonetti M; Giansanti P; Heck A; den Hertog J
PLoS One; 2014; 9(9):e106682. PubMed ID: 25184253
[TBL] [Abstract][Full Text] [Related]
4. PZR coordinates Shp2 Noonan and LEOPARD syndrome signaling in zebrafish and mice.
Paardekooper Overman J; Yi JS; Bonetti M; Soulsby M; Preisinger C; Stokes MP; Hui L; Silva JC; Overvoorde J; Giansanti P; Heck AJ; Kontaridis MI; den Hertog J; Bennett AM
Mol Cell Biol; 2014 Aug; 34(15):2874-89. PubMed ID: 24865967
[TBL] [Abstract][Full Text] [Related]
5. Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.
Noda S; Takahashi A; Hayashi T; Tanuma S; Hatakeyama M
Biochem Biophys Res Commun; 2016 Jan; 469(4):1133-9. PubMed ID: 26742426
[TBL] [Abstract][Full Text] [Related]
6. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects.
Kontaridis MI; Swanson KD; David FS; Barford D; Neel BG
J Biol Chem; 2006 Mar; 281(10):6785-92. PubMed ID: 16377799
[TBL] [Abstract][Full Text] [Related]
7. PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots?
Lauriol J; Kontaridis MI
Trends Cardiovasc Med; 2011 May; 21(4):97-104. PubMed ID: 22681964
[TBL] [Abstract][Full Text] [Related]
8. Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner.
Zheng H; Yu WM; Waclaw RR; Kontaridis MI; Neel BG; Qu CK
Sci Signal; 2018 Mar; 11(522):. PubMed ID: 29559584
[TBL] [Abstract][Full Text] [Related]
9. Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature.
De Rocca Serra-Nédélec A; Edouard T; Tréguer K; Tajan M; Araki T; Dance M; Mus M; Montagner A; Tauber M; Salles JP; Valet P; Neel BG; Raynal P; Yart A
Proc Natl Acad Sci U S A; 2012 Mar; 109(11):4257-62. PubMed ID: 22371576
[TBL] [Abstract][Full Text] [Related]
10. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation.
Araki T; Mohi MG; Ismat FA; Bronson RT; Williams IR; Kutok JL; Yang W; Pao LI; Gilliland DG; Epstein JA; Neel BG
Nat Med; 2004 Aug; 10(8):849-57. PubMed ID: 15273746
[TBL] [Abstract][Full Text] [Related]
11. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.
Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM
Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348
[TBL] [Abstract][Full Text] [Related]
12. Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11).
Qiu W; Wang X; Romanov V; Hutchinson A; Lin A; Ruzanov M; Battaile KP; Pai EF; Neel BG; Chirgadze NY
BMC Struct Biol; 2014 Mar; 14():10. PubMed ID: 24628801
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations.
Yu ZH; Zhang RY; Walls CD; Chen L; Zhang S; Wu L; Liu S; Zhang ZY
Biochemistry; 2014 Jul; 53(25):4136-51. PubMed ID: 24935154
[TBL] [Abstract][Full Text] [Related]
14. Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis.
Stewart RA; Sanda T; Widlund HR; Zhu S; Swanson KD; Hurley AD; Bentires-Alj M; Fisher DE; Kontaridis MI; Look AT; Neel BG
Dev Cell; 2010 May; 18(5):750-62. PubMed ID: 20493809
[TBL] [Abstract][Full Text] [Related]
15. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway.
Tidyman WE; Rauen KA
Expert Rev Mol Med; 2008 Dec; 10():e37. PubMed ID: 19063751
[TBL] [Abstract][Full Text] [Related]
16. Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome.
Nakamura T; Colbert M; Krenz M; Molkentin JD; Hahn HS; Dorn GW; Robbins J
J Clin Invest; 2007 Aug; 117(8):2123-32. PubMed ID: 17641779
[TBL] [Abstract][Full Text] [Related]
17. Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways.
Kontaridis MI; Yang W; Bence KK; Cullen D; Wang B; Bodyak N; Ke Q; Hinek A; Kang PM; Liao R; Neel BG
Circulation; 2008 Mar; 117(11):1423-35. PubMed ID: 18316486
[TBL] [Abstract][Full Text] [Related]
18. Genetic and pathogenetic aspects of Noonan syndrome and related disorders.
Zenker M
Horm Res; 2009 Dec; 72 Suppl 2():57-63. PubMed ID: 20029240
[TBL] [Abstract][Full Text] [Related]
19. New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling.
Schramm C; Edwards MA; Krenz M
J Biol Chem; 2013 Jun; 288(25):18335-44. PubMed ID: 23673659
[TBL] [Abstract][Full Text] [Related]
20. PTPN11 mutations and genotype-phenotype correlations in Noonan and LEOPARD syndromes.
Ogata T; Yoshida R
Pediatr Endocrinol Rev; 2005 Jun; 2(4):669-74. PubMed ID: 16208280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
